Mitoxantrone

 Mitoxantrone is mediated antineoplastic agent with a strong immunological effects, including by inhibiting immune B cells and lymphocytes-T, is much less toxic anti-cancer drugs other, is the most common serious side effects cardiotoxicity. This compound is the subject of three trials for the treatment of MS in recent years.

Last placebo-controlled, randomized, conducted in Italy of 51 patients with RRMS. The treatment was to be in the 8 mg/m2 administered intravenously once a month for a year. A were measured downward trend in disease activity by evaluating clinical outcomes and magnetic resonance imaging (MRI) and shown in this study.

Conducted last placebo-controlled, randomized, with the expected duration of two years in Italy, from 51 patients with RRMS. The treatment was to be in the 8 mg/m2 administered intravenously once a month for a year. A were measured downward trend in disease activity by evaluating clinical outcomes and magnetic resonance imaging (MRI) and shown in this study.